公开(公告)号：US10851065B2

公开(公告)日：2020-12-01

申请号：US15713107

申请日：2017-09-22

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Mark Bock ,  Ming-Hong Hao ,  Manav Korpal ,  Vijay Kumar Nyavanandi ,  Xiaoling Puyang ,  Susanta Samajdar ,  Peter Gerard Smith ,  John Wang ,  Guo Zhu Zheng ,  Ping Zhu

IPC: A01N43/00 ,  A01N43/46 ,  A61K31/55 ,  C07D231/56 ,  C07D403/12 ,  C07D471/14 ,  C07D403/06 ,  C07D401/06 ,  C07D401/14

Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.

公开(公告)号：US12251394B2

公开(公告)日：2025-03-18

申请号：US17058817

申请日：2019-05-31

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Dae-Shik Kim ,  Frank Fang ,  Atsushi Endo ,  Hyeong-Wook Choi ,  Ming-Hong Hao ,  Xingfeng Bao ,  Kuan-Chun Huang

IPC: A61K31/7084 ,  A61P35/04

Abstract: Provided herein are methods for the treatment of bladder cancer.

公开(公告)号：US11926619B2

公开(公告)日：2024-03-12

申请号：US17045952

申请日：2019-04-08

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Gregg F. Keaney ,  John Wang ,  Baudouin Gerard ,  Kenzo Arai ,  Xiang Liu ,  Guo Zhu Zheng ,  Kazunobu Kira ,  Lisa A. Marcaurelle ,  Marta Nevalainen ,  Ming-Hong Hao ,  Morgan Welzel O'Shea ,  Parcharee Tivitmahaisoon ,  Sudeep Prajapati ,  Tuoping Luo ,  Nicholas C. Gearhart ,  Jason T. Lowe ,  Yoshihiko Kotake ,  Satoshi Nagao ,  Regina Mikie Kanada Sonobe ,  Masayuki Miyano ,  Norio Murai ,  Andrew Cook ,  Shelby Ellery ,  Atsushi Endo ,  James Palacino ,  Dominic Reynolds

IPC: C07D407/12 ,  A61K31/365 ,  A61K31/4427 ,  A61K31/497 ,  A61K45/06 ,  A61P35/00 ,  C07D313/00 ,  C07D405/12 ,  C07D405/14 ,  C07D407/06 ,  C07D407/14 ,  C07D413/12 ,  C07D417/12 ,  C07D487/08 ,  C07D487/10 ,  C07D491/107

CPC classification number: C07D407/06 ,  A61K45/06 ,  A61P35/00 ,  C07D313/00 ,  C07D405/12 ,  C07D405/14 ,  C07D413/12 ,  C07D417/12 ,  C07D487/08 ,  C07D487/10 ,  C07D491/107

Abstract: The present disclosure provides novel pladienolide compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancers, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are methods of treating cancers by administering at least one compound disclosed herein and at least one additional therapy.

公开(公告)号：US11498916B2

公开(公告)日：2022-11-15

申请号：US16722838

申请日：2019-12-20

Applicant: Eisai R&D Management Co., Ltd.

Inventor： George Moniz ,  Kristen Sanders ,  Arani Chanda ,  Kenshi Yoshida ,  Ming-Hong Hao ,  Dominic Reynolds ,  Sudeep Prajapati ,  Anand Selvaraj ,  Takashi Satoh ,  John Wang

IPC: C07D403/12 ,  C07D239/48 ,  A61K31/505

Abstract: A number of crystalline forms of N-(2-((6-(3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-methylureido)pyrimidin-4-yl)amino)-5-(4-ethylpiperazin-1-y1)phenyl)acrylamide are provided. These include a crystalline free base form, a crystalline monohydrochloride salt form, a crystalline dihydrochloride salt form, and a crystalline ethanesulfonate salt form. Methods of making and using crystalline compounds are also provided.

公开(公告)号：US20190337921A1

公开(公告)日：2019-11-07

申请号：US16349508

申请日：2017-11-22

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Mark Bock ,  Ming-Hong Hao ,  Manav Korpal ,  Vijay Kumar Nyavanandi ,  Xiaoling Puyang ,  Susanta Samajdar ,  Peter Gerard Smith ,  John Wang ,  Guo Zhu Zheng ,  Ping Zhu ,  Lorna Helen Mitchell ,  Nicholas Larsen ,  Nathalie Rioux

IPC: C07D401/06 ,  C07D209/08 ,  C07D401/14 ,  A61P35/00

Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.

公开(公告)号：US11339188B2

公开(公告)日：2022-05-24

申请号：US16781352

申请日：2020-02-04

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Dae-Shik Kim ,  Frank Fang ,  Atsushi Endo ,  Hyeong-wook Choi ,  Ming-Hong Hao ,  Xingfeng Bao ,  Kuan-Chun Huang

IPC: C07H21/02 ,  A61P35/02 ,  A61K31/7084 ,  C07F9/6587 ,  C07H21/00 ,  A61P31/04 ,  A61P37/04

Abstract: Provided herein are compounds useful for the treatment of cancer.

公开(公告)号：US10537571B2

公开(公告)日：2020-01-21

申请号：US15627851

申请日：2017-06-20

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Dominic Reynolds ,  Ming-Hong Hao ,  John Wang ,  Sudeep Prajapati ,  Takashi Satoh ,  Anand Selvaraj

IPC: A61K31/505 ,  A61K31/506 ,  A61K31/5377

Abstract: Provided herein are compounds of Formula I useful as FGFR4 inhibitors, as well as methods of use of the same.

公开(公告)号：US10246480B2

公开(公告)日：2019-04-02

申请号：US15898533

申请日：2018-02-17

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Dae-Shik Kim ,  Frank Fang ,  Atsushi Endo ,  Hyeong-Wook Choi ,  Ming-Hong Hao ,  Xingfeng Bao ,  Kuan-Chun Huang

IPC: C07H21/02 ,  A61P35/02 ,  A61K31/7084 ,  C07F9/6587 ,  C07H21/00 ,  A61P31/04 ,  A61P37/04

Abstract: Provided herein are compounds useful for the treatment of cancer.

公开(公告)号：US10912774B2

公开(公告)日：2021-02-09

申请号：US16717080

申请日：2019-12-17

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Dominic Reynolds ,  Ming-Hong Hao ,  John Wang ,  Sudeep Prajapati ,  Takashi Satoh ,  Anand Selvaraj

IPC: A61K31/505 ,  A61K31/506 ,  A61K31/5377

Abstract: Provided herein are compounds of Formula I useful as FGFR4 inhibitors, as well as methods of use of the same.

公开(公告)号：US20200255415A1

公开(公告)日：2020-08-13

申请号：US16349479

申请日：2017-11-22

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Mark Bock ,  Ming-Hong Hao ,  Manav Korpal ,  Vijay Kumar Nyavanandi ,  Xiaoling Puyang ,  Susanta Samajdar ,  Peter Gerard Smith ,  John Wang ,  Guo Zhu Zheng ,  Ping Zhu ,  Lorna Helen Mitchell ,  Nicholas Larsen ,  Nathalie Rioux ,  Sudeep Prajapati ,  Dominic Reynolds ,  Morgan O'Shea ,  Thiwanka Samarakoon

IPC: C07D413/14 ,  A61P35/00 ,  C07D231/56 ,  C07D401/10 ,  C07D401/14 ,  C07D401/12 ,  C07D413/12 ,  C07D403/10

Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.